CAM
NBIX icon

Cresset Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Cresset Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,855
Closed -$329K – 2054
2024
Q3 		$329K Sell
2,855
-289
-9% -$39.6K ﹤0.01% 1757
2024
Q2 		$433K Buy
3,144
+145
+5% +$19.9K ﹤0.01% 1514
2024
Q1 		$414K Sell
2,999
-554
-16% -$75.7K ﹤0.01% 1432
2023
Q4 		$468K Buy
3,553
+101
+3% +$11.6K ﹤0.01% 1269
2023
Q3 		$388K Buy
3,452
+663
+24% +$69.8K ﹤0.01% 1312
2023
Q2 		$263K Buy
+2,789
New +$273K ﹤0.01% 1586
2021
Q4 		– Sell
-2,469
Closed -$237K – 1235
2021
Q3 		$237K Buy
+2,469
New +$233K ﹤0.01% 954
2019
Q2 		– Sell
-922
Closed -$81K – 1239
2019
Q1 		$81K Buy
922
+21
+2% +$1.75K ﹤0.01% 621
2018
Q4 		$64K Buy
+901
New +$86.3K ﹤0.01% 422

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Cresset Asset Management's NBIX Position: Q4 2024 in Review

Cresset Asset Management sold out of Neurocrine Biosciences (NBIX) in Q4 2024, closing a stake of 2,855 shares — an estimated $329K sold.

Cresset Asset Management first reported a position in NBIX in Q4 2018 and held it in 9 quarters. The position peaked at $468K in Q4 2023. 600 funds tracked by Wall St. Rank hold NBIX as of Q4 2024.

  • Cresset Asset Management reported no remaining Neurocrine Biosciences position as of Q4 2024 after selling out during the quarter.
  • Cresset Asset Management sold 2,855 Neurocrine Biosciences shares in Q4 2024, an estimated $329K.
  • Cresset Asset Management first reported a position in Neurocrine Biosciences in Q4 2018 and held it in 9 quarters.
  • Cresset Asset Management's Neurocrine Biosciences position peaked at $468K in Q4 2023.
  • 600 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2024.

Based on Cresset Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.